Skip to main content

Advertisement

SpringerLink
Log in

Cancer nanomedicine: is targeting our target?

  • Comment
  • Published:

From Nature Reviews Materials

View current issue Sign up to alerts

An Erratum to this article was published on 09 September 2016

Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Torrice, M. Does nanomedicine have a delivery problem? ACS Cent. Sci. 2, 434–437 (2016).

    Article  CAS  Google Scholar 

  2. Venditto, V.J. & Szoka, F.C. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65, 80–88 (2013).

    Article  CAS  Google Scholar 

  3. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

    Article  CAS  Google Scholar 

  4. Lammers, T., Rizzo, L.Y., Storm, G. & Kiessling, F. Personalized nanomedicine. Clin. Cancer Res. 18, 4889–4894 (2012).

    Article  CAS  Google Scholar 

  5. Tietjen, G.T. & Saltzman, W.M. Nanomedicine gets personal. Sci. Transl. Med. 7, 314fs47 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

T.L. gratefully acknowledges support by the European Research Council (StG-309495, PoC-680882) and by the German Research Foundation (LA 2937/1-2).

Author information

Authors and Affiliations

  1. Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, 52074, Germany

    Twan Lammers & Fabian Kiessling

  2. Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, 7500, AE, The Netherlands

    Twan Lammers & Gert Storm

  3. Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584, CG, The Netherlands

    Twan Lammers, Wim Hennink, Daan Crommelin & Gert Storm

  4. Pharmaceutical Science, Innovative Medicines, AstraZeneca, Macclesfield, SK10 2NA, UK

    Marianne Ashford

Authors
  1. Twan Lammers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabian Kiessling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marianne Ashford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wim Hennink
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daan Crommelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gert Storm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Twan Lammers or Daan Crommelin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lammers, T., Kiessling, F., Ashford, M. et al. Cancer nanomedicine: is targeting our target?. Nat Rev Mater 1, 16069 (2016). https://doi.org/10.1038/natrevmats.2016.69

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/natrevmats.2016.69

  • Springer Nature Limited

This article is cited by

Search

Navigation